Background: Inflammatory theories in schizophrenia have gained increasing recognition and acceptance in recent years. The evidence supporting a role of altered inflammatory processes in the etiology and pathophysiology of schizophrenia involves early-life exposure to infectious pathogens or inflammatory stimuli, increased expression of cytokines and other mediators of inflammation in the adult central nervous system (CNS) and periphery, as well as signs of glial anomalies. Given the role of dopaminergic deregulation in the pathophysiology of schizophrenia, inflammatory processes in the midbrain may contribute to dopamine abnormalities in the midbrain and its subcortical and cortical output regions. Here, we tested this hypothesis using an established neurodevelopmental mouse model with relevance to schizophrenia, namely the maternal immune activation (MIA) model. Methods: Pregnant C57BL6/N mice on gestation day 17 were treated with the viral mimetic polyriboinosinic-polyribocytidilic acid (poly(I:C)) or vehicle control solution. We then quantified the gene transcripts of an array of pro-inflammatory cytokines, acute phase proteins, and dopaminergic markers in the midbrain of MIA offspring (N=32) and control offspring (N= 32) at adult age. We also assessed the cell density of microglial cells expressing Iba1 and CD68 by immunohistochemistry to ascertain whether putative inflammatory changes are accompanied by microglia anomalies. Given the large sample sizes, we performed twostep recursive cluster analyses in order to identify possible subgroups of offspring that are characterized by "high" and "low" inflammatory profiles. Results: When considering the entire treatment group, MIA-exposed offspring displayed significantly increased expression of several inflammatory cytokines in the ventral midbrain, including IL-1b (p < 0.01), TNF-a (p < 0.01) and SERPINA3 (p < 0.01). These inflammatory changes occurred in the absence of overt microglia anomalies but were paralleled by changes in dopaminergic markers. The two-step cluster analyses further identified subgroups of MIA-exposed offspring that are characterized by a "high" (41 %, N = 13) and "low" (59 %, N = 19) inflammatory profiles. The "high" inflammatory subgroup of MIA-exposed offspring was defined by marked elevations of SERPINA3, IL-1β, IL-6, and TNFα mRNA levels (all p's < 0.01). Discussion: Maternal immune activation during pregnancy causes persistent signs of inflammation in the offspring's midbrain. In agreement with post-mortem studies in schizophrenia, these inflammatory abnormalities are clearly noticeable in a subgroup of MIA-exposed offspring only. Hence, prenatal immune activation may be one of the factors inducing lasting inflammatory changes relevant to (some cases of) schizophrenia and may contribute to dopaminergic dysfunctions in this disorder.
Methods: Pregnant SD rat dams were exposed to poly (I:C) on GD15 (4 mg/kg, i.v.; n=5; POL) to induce MIA, or saline (n=5; CON) as a control. At 4 months of age, male offspring from CON and POL (n=2 per litter), were randomly allocated to treatment with either haloperidol (0.5 mg/kg/d s.c.) or vehicle for 28 days by osmotic minipumps, giving four groups: CON/vehicle; CON/haloperidol; POL/vehicle and POL/haloperidol (all n=10). After 28d treatment, animals were culled and perfused transcardially with 4% PFA. Fixed brain tissues were dissected, cryoprotected and microtome sectioned (1 in 12 series, 40 µm thick). Serial sections were stained for Iba1 as a marker of microglia using an immunoperoxidase protocol. The density and morphology (soma size) of Iba1+ microglia were then assessed in the corpus striatum (CS) and anterior cingulate cortex (ACC) using unbiased stereology. Data were analysed using 2x2 ANOVA in SPSS with main effects of prenatal, postnatal and pre x post-natal interactions.
Results: There were significant main effects of prenatal exposure to POL on Iba1+ microglia density in the CS (F(1,32)=18.09; p<0.001) and the ACC (F(1,32)=5.04; p<0.05) and for Iba1+ microglia soma sizes (increased) in POL offspring in both the CS (F(1,32)=88.5; p<0.001) and ACC (F(1,32)=45.06; p<0.001). There were no main effects of postnatal treatment (vehicle or haloperidol) on Iba1+ microglia density in either the CS or ACC, but there were main effects of postnatal treatment for Iba1+ microglia soma size in both CS (F(1,32)=17.3; p<0.001) and ACC (F(1,32)=7.69; p<0.01). Strikingly, there were significant interactions between pre-and post-natal treatments for both Iba1+ density in the CS (F(1,32)=5.15; p<0.05) and PFC (F(1,32)=9.43; p<0.01) as well as soma size in the CS (F(1,32)=11.6; p<0.01) and ACC (F(1,32)=11.7; p<0.01). Post-hoc testing on this interaction confirmed a significant increase in both Iba1+ density and soma size in poly(I:C)-exposed offspring treated with haloperidol, relative to all other groups in both the CS (p<0.01) and ACC (p<0.01). Discussion: Our data suggest increased microglial density and activation in the CS and PFC of rats exposed to POL in utero. Haloperidol treatment for 28 days replicating clinically comparable dosing and pharmacokinetics did not affect microglia density in saline-exposed offspring, but increased Iba1+ soma size in both CS and ACC, also suggestive of microglial activation. Strikingly, there were significant interactions between prenatal POL exposure and post-natal haloperidol treatment, leading to significantly increased microglia density and soma size in both CS and ACC. Taken together, these preliminary data suggest adult haloperidol treatment may interact with prenatal immune activation to worsen neuroinflammation. Background: Postnatal consequences of prenatal immune activation mimic a broad spectrum of neuro-psycho-pathological features phenotypic of schizophrenia (SCZ). We previously showed that SCZ-relevant behavioral
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